INTERVIEW: Unravelling The Strategies Behind Sanofi's China Surge
This article was originally published in PharmAsia News
The figures are screaming for attention. While many multinationals are grappling with lower single-digit growth in China, Sanofi logged a 20% increase last year, despite the country’s overall economic downturn. The figure was testament to the French group’s creative approaches to county-level opportunities and integrated disease management in a market filled with complexities and uncertainties. Sanofi Pharma China GM Jean-Christophe Pointeau shares some of the secrets in an exclusive interview.